157 related articles for article (PubMed ID: 35027164)
1. [Combining surgery and medical treatments for ovarian cancer: Is there an optimal strategy?].
Thomas QD; Quesada S; D'Hondt V; Belaroussi I; Laas E; Classe JM; Fabbro M; Colombo PE; Fiteni F
Bull Cancer; 2022 Feb; 109(2):197-215. PubMed ID: 35027164
[TBL] [Abstract][Full Text] [Related]
2. [Surgery for advanced stage ovarian cancer: Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa].
Ferron G; Narducci F; Pouget N; Touboul C
Gynecol Obstet Fertil Senol; 2019 Feb; 47(2):197-213. PubMed ID: 30792175
[TBL] [Abstract][Full Text] [Related]
3. To compare the optimal cytoreduction rate in advanced epithelial ovarian cancer stage III/IV after 3 versus 6 cycles of neoadjuvant chemotherapy.
Kumari A; Thakur M; Saha SC; Suri V; Prasad GRV; Patel FD; Radhika S
J Obstet Gynaecol; 2021 May; 41(4):616-620. PubMed ID: 32811236
[TBL] [Abstract][Full Text] [Related]
4. Prise en charge chirurgicale du cancer épithélial de l'ovaire - première ligne et première rechute: Surgical management of epithelial ovarian cancer - first line and first relapse.
Classe JM; Joly F; Lécuru F; Morice P; Pomel C; Selle F; You B
Bull Cancer; 2021 Dec; 108(9S1):S13-S21. PubMed ID: 34955158
[TBL] [Abstract][Full Text] [Related]
5. [Epithelial ovarian cancer and elderly patients. Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa].
Falandry C; Gouy S
Gynecol Obstet Fertil Senol; 2019 Feb; 47(2):238-249. PubMed ID: 30712964
[TBL] [Abstract][Full Text] [Related]
6. Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
Yao SE; Tripcony L; Sanday K; Robertson J; Perrin L; Chetty N; Land R; Garrett A; Obermair A; Nascimento M; Tang A; Jagasia N; Singh P; Nicklin J
Int J Gynecol Cancer; 2020 Dec; 30(12):1935-1942. PubMed ID: 33122245
[TBL] [Abstract][Full Text] [Related]
7. Delays from neoadjuvant chemotherapy to interval debulking surgery and survival in ovarian cancer.
Liu YL; Zhou QC; Iasonos A; Filippova OT; Chi DS; Zivanovic O; Sonoda Y; Gardner G; Broach V; OCearbhaill R; Konner JA; Aghajanian CA; Long K; Tew W
Int J Gynecol Cancer; 2020 Oct; 30(10):1554-1561. PubMed ID: 32522770
[TBL] [Abstract][Full Text] [Related]
8. Survival outcome and perioperative complication related to neoadjuvant chemotherapy with carboplatin and paclitaxel for advanced ovarian cancer: A systematic review and meta-analysis.
Machida H; Tokunaga H; Matsuo K; Matsumura N; Kobayashi Y; Tabata T; Kaneuchi M; Nagase S; Mikami M
Eur J Surg Oncol; 2020 May; 46(5):868-875. PubMed ID: 31818526
[TBL] [Abstract][Full Text] [Related]
9. Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850).
Fagotti A; Ferrandina MG; Vizzielli G; Pasciuto T; Fanfani F; Gallotta V; Margariti PA; Chiantera V; Costantini B; Gueli Alletti S; Cosentino F; Scambia G
Int J Gynecol Cancer; 2020 Nov; 30(11):1657-1664. PubMed ID: 33028623
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of secondary cytoreductive surgery for patients with platinum-sensitive recurrent ovarian cancer.
Gockley A; Melamed A; Cronin A; Bookman MA; Burger RA; Cristae MC; Griggs JJ; Mantia-Smaldone G; Matulonis UA; Meyer LA; Niland J; O'Malley DM; Wright AA
Am J Obstet Gynecol; 2019 Dec; 221(6):625.e1-625.e14. PubMed ID: 31207237
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery and the Risk of Platinum Resistance in Epithelial Ovarian Cancer.
da Costa AA; Valadares CV; Baiocchi G; Mantoan H; Saito A; Sanches S; Guimarães AP; Achatz MI
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S971-8. PubMed ID: 26014155
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of advanced ovarian carcinoma: surgery before chemotherapy or chemotherapy before surgery?].
Piura B
Harefuah; 2014 Sep; 153(9):524-6, 558-9. PubMed ID: 25417488
[TBL] [Abstract][Full Text] [Related]
13. Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial concept.
Jiang R; Zhu J; Kim JW; Liu J; Kato K; Kim HS; Zhang Y; Zhang P; Zhu T; Aoki D; Yu A; Chen X; Wang X; Zhu D; Zhang W; Jia H; Shi T; Gao W; Yin S; Feng Y; Xiang L; Okamoto A; Zang R
J Gynecol Oncol; 2020 Sep; 31(5):e86. PubMed ID: 32808504
[TBL] [Abstract][Full Text] [Related]
14. [Retrospective study: Late surgery post chemotherapy versus after 3-4 cures in treatment of advanced ovarian cancer].
de Fréminville Q; Licaj I; Frenel JS; Hamel-Senecal L; Thomas G; Brachet PE; Coquan E; Leconte A; Classe JM; Joly F
Bull Cancer; 2020 Feb; 107(2):157-170. PubMed ID: 31858981
[TBL] [Abstract][Full Text] [Related]
15. [Diagnostic and prognostic value of tumor markers, scores (clinical and biological) algorithms, in front of an ovarian mass suspected of an epithelial ovarian cancer: Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa].
Bendifallah S; Body G; Daraï E; Ouldamer L
Gynecol Obstet Fertil Senol; 2019 Feb; 47(2):134-154. PubMed ID: 30733191
[TBL] [Abstract][Full Text] [Related]
16. Tertiary cytoreduction for recurrent ovarian carcinoma: An updated and expanded analysis.
Manning-Geist BL; Chi DS; Long Roche K; Zivanovic O; Sonoda Y; Gardner GJ; O'Cearbhaill RE; Abu-Rustum NR; Leitao MM
Gynecol Oncol; 2021 Aug; 162(2):345-352. PubMed ID: 34045053
[TBL] [Abstract][Full Text] [Related]
17. [Part I drafted from the short text of the French Guidelines entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY and endorsed by INCa. (Diagnosis management, surgery, perioperative care, and pathological analysis)].
Lavoué V; Huchon C; Akladios C; Alfonsi P; Bakrin N; Ballester M; Bendifallah S; Bolze PA; Bonnet F; Bourgin C; Chabbert-Buffet N; Collinet P; Courbiere B; De la Motte Rouge T; Devouassoux-Shisheboran M; Falandry C; Ferron G; Fournier L; Gladieff L; Golfier F; Gouy S; Guyon F; Lambaudie E; Leary A; Lécuru F; Lefrère-Belda MA; Leblanc E; Lemoine A; Narducci F; Ouldamer L; Pautier P; Planchamp F; Pouget N; Ray-Coquard I; Rousset-Jablonski C; Sénéchal-Davin C; Touboul C; Thomassin-Naggara I; Uzan C; You B; Daraï E
Gynecol Obstet Fertil Senol; 2019 Feb; 47(2):100-110. PubMed ID: 30686724
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant Chemotherapy for Elderly Patients with Advanced Stage Ovarian Carcinoma.
Salman L; Ben-Haroush A; Sabah G; Jakobson-Setton A; Tsoref D; Raban O; Yeoshoua E; Eitan R
Isr Med Assoc J; 2020 Feb; 22(2):75-78. PubMed ID: 32043322
[TBL] [Abstract][Full Text] [Related]
19. Impact of residual disease at interval debulking surgery on platinum resistance and patterns of recurrence for advanced-stage ovarian cancer.
Greer A; Gockley A; Manning-Geist B; Melamed A; Sisodia RC; Berkowitz R; Horowitz N; Del Carmen M; Growdon WB; Worley M
Int J Gynecol Cancer; 2021 Oct; 31(10):1341-1347. PubMed ID: 34429355
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors of overall survival for patients with FIGO stage IIIc or IVa ovarian cancer treated with neo-adjuvant chemotherapy followed by interval debulking surgery: A multicenter cohort analysis from the FRANCOGYN study group.
Vincent L; Jankowski C; Ouldamer L; Ballester M; Bendifallah S; Bolze PA; Akladios C; Costaz H; Lavoué V; Canlorbe G; Collinet P; Touboul C; Huchon C; Bricou A; Dridi S; Padéano MM; Bengrine L; Arnould L; Coutant C;
Eur J Surg Oncol; 2020 Sep; 46(9):1689-1696. PubMed ID: 32417154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]